A new project at the CRC for Cell Therapy Manufacturing (CTM CRC), in collaboration with the Women’s and Children’s Hospital and through the generous support of the Women’s and Children’s Hospital Foundation may help to advance the curative potential of immunotherapies for cancer.
The project involves taking a patient’s own immune cells and engineering them to recognise and attack tumours, thus harnessing the body’s own healing potential. Known as chimeric antigen receptor (CAR) T cell therapy, this approach has already produced remarkable responses in clinical trials involving patients with advanced blood cancers.
“Over the last few years, a high percentage of patients treated with CAR T cell therapies have seen their cancer regress to the point of being undetectable. The results seen with CAR T technology are essentially unprecedented and have the potential to revolutionise cancer treatment,” says Dr Justin Coombs, General Manager at CTM CRC.
“These early clinical results have also generated enormous commercial interest in CAR T cell technologies, which is fuelling rapid technology innovation in the field.”
“The aim of the CRC collaborative project is to explore the potential development of a new CAR T cell that could be active against a broad range of cancers, rather than just leukaemia, particularly those prevalent in childhood,” Dr Coombs said.
Work on the project has begun at the Women’s and Children’s Hospital in Adelaide and is being led by Associate Professor Simon Barry, a world expert in T cell biology.
Mr Sam Tolley, CEO of the Women’s and Children’s Hospital Foundation, said that the project was not only great news for cancer research, but also for South Australia.
“We are very proud to be supporting this ground breaking research at our iconic Women’s and Children’s Hospital.”
“With around 50 children diagnosed with cancer every year in SA, this research has the potential to change many lives and may even lead to a cure. The future of our health relies upon quality research, so the more support we can offer in this area now, the better treatments families will have access to,” said Mr Tolley.
Dr Sherry Kothari, Managing Director at CTM CRC says that this project highlights the benefits that come from the collaborative approach to research in the CRC.
“With a mission to develop, translate and commercialise promising cell therapy technologies, CTM CRC is ideally positioned to take a lead approach in an innovative, collaborative project such as this. We have some tremendous capability in Australia and I am delighted that we can help harness some of this to create value in Australia for the benefit of patients here and abroad.”
Click here for media release